Roxicodone vs. Oxycodone: Are They the Same Drug?

Roxicodone vs oxycodone refer to the same active ingredient, oxycodone hydrochloride, differing only in brand name versus generic identity.

Roxicodone is a brand name for immediate-release oxycodone HCl tablets in 5mg, 15mg, and 30mg strengths. Generic oxycodone encompasses the same immediate-release formulation plus extended-release (OxyContin) and combination products containing acetaminophen (Percocet).

Whether labeled Roxicodone or generic oxycodone IR, the pharmacological activity, mu-opioid receptor binding profile, and substance use disorder risk are identical. What actually separates one oxycodone product from another is not the active drug itself, but its formulation, duration of action, and whether it includes a secondary compound like acetaminophen.

Key Takeaways

• Roxicodone is a brand name for immediate-release oxycodone hydrochloride; it and generic oxycodone IR contain the same active ingredient at the same pharmacological potency.
• Synthetic opioids including oxycodone were involved in the vast majority of the 107,941 drug overdose deaths recorded in the U.S. in 2022, according to the Centers for Disease Control and Prevention.
• Oxycodone is approximately 1.5 times more potent than morphine by equianalgesic dose; it is less potent than hydromorphone, oxymorphone, and fentanyl.
• Approximately 5.6 million Americans aged 12 or older met DSM-5-TR criteria for opioid use disorder in 2022, according to SAMHSA’s National Survey on Drug Use and Health.
• The DEA classifies all oxycodone formulations, including Roxicodone, as Schedule II controlled substances, reflecting high abuse potential and a narrow therapeutic-to-misuse window.

What Is Roxicodone?

Roxicodone is the brand name for an immediate-release oxycodone hydrochloride tablet, available in 5mg, 15mg, and 30mg strengths, indicated for the management of moderate to severe acute pain where around-the-clock dosing is not required.

Roxicodone as a Brand Name

Roxicodone was originally developed by Xanodyne Pharmaceuticals and subsequently licensed to other manufacturers. The formulation contains no acetaminophen, no acetylsalicylic acid, and no other secondary analgesic compound. Its active pharmaceutical ingredient is oxycodone hydrochloride, the same compound present in generic oxycodone IR tablets, Percocet, OxyContin, and Oxaydo. Roxicodone’s brand-name status confers no pharmacological advantage over generic immediate-release oxycodone HCl; both produce identical mu-opioid receptor binding kinetics and identical onset and duration profiles.

Roxicodone Available Strengths and DEA Status

Roxicodone is manufactured in three tablet strengths covering the full immediate-release oxycodone dosage range most commonly used in clinical practice.

• Roxicodone 5mg: Round, white tablet; oxycodone HCl 5mg; lowest immediate-release starting dose for opioid-naive patients per ASAM pain management guidelines
• Roxicodone 15mg: Round, green tablet; oxycodone HCl 15mg; intermediate dose for partial opioid tolerance
• Roxicodone 30mg: Round, blue tablet; oxycodone HCl 30mg; highest Roxicodone strength; visually similar to counterfeit M30 pills containing illicitly manufactured fentanyl
• DEA Schedule II: High abuse potential, currently accepted medical use with severe restrictions, and potential for severe psychological or physical dependence

What Is Oxycodone? Formulations and Key Distinctions

Oxycodone is a semi-synthetic opioid analgesic derived from thebaine, an alkaloid of the opium poppy Papaver somniferum, and it is the active pharmaceutical ingredient across multiple branded and generic formulations that differ in release mechanism and secondary ingredients.

Immediate-Release Oxycodone HCl

Immediate-release oxycodone HCl includes both Roxicodone and its generic equivalents. These formulations deliver the full dose rapidly into systemic circulation, producing peak plasma concentrations within 1 to 2 hours of ingestion. Immediate-release oxycodone provides analgesia for 4 to 6 hours per dose, making it suitable for acute pain management but presenting higher misuse risk per dose compared to extended-release formats due to the rapid onset of euphoric reward effects that NIDA Director Dr. Nora Volkow’s neurobiological research identifies as the primary driver of dopaminergic reinforcement in opioid use disorder development.

Extended-Release Oxycodone (OxyContin)

OxyContin contains oxycodone HCl in a polymer matrix designed to release the drug over 12 hours, delivering therapeutic concentrations with reduced peak-to-trough fluctuation. OxyContin was developed by Purdue Pharma in 1996 and contributes directly to the initiation of the opioid epidemic through aggressive marketing of extended-release formulations for non-cancer pain. The abuse-deterrent formulation introduced in 2010 replaced the original OxyContin, partially reducing injection misuse but not oral misuse of crushed tablets.

Oxycodone-Acetaminophen Combinations (Percocet)

Percocet combines oxycodone HCl with acetaminophen 325mg in a single immediate-release tablet. The acetaminophen component provides synergistic analgesia via central prostaglandin inhibition and theoretically deters escalating misuse by introducing hepatotoxic risk at high doses. Available in 2.5mg, 5mg, 7.5mg, and 10mg oxycodone strengths, Percocet is the most prescribed opioid-acetaminophen combination in the United States.

Roxicodone vs. Oxycodone: Full Formulation Comparison

Roxicodone, generic oxycodone IR, Percocet, and OxyContin share the same active ingredient but differ in every clinically meaningful characteristic except receptor binding mechanism.

Feature	Roxicodone	Generic Oxycodone IR	Percocet	OxyContin
Active ingredient	Oxycodone HCl	Oxycodone HCl	Oxycodone HCl + APAP 325mg	Oxycodone HCl
Formulation type	Immediate-release	Immediate-release	Immediate-release	Extended-release
Onset of action	10–30 minutes	10–30 minutes	10–30 minutes	1–2 hours
Duration of analgesia	4–6 hours	4–6 hours	4–6 hours	12 hours
Available strengths	5mg, 15mg, 30mg	5mg, 10mg, 15mg, 20mg, 30mg	2.5mg, 5mg, 7.5mg, 10mg	10–80mg
Acetaminophen	None	None	325mg per tablet	None
DEA Schedule	Schedule II	Schedule II	Schedule II	Schedule II
Abuse potential	High (rapid onset)	High (rapid onset)	High (rapid onset)	High (abuse-deterrent reformulation)

How Oxycodone HCl Works in the Brain

Oxycodone HCl produces analgesia, sedation, and euphoria through agonist binding at mu-opioid receptors throughout the central and peripheral nervous system, with its addictive potential arising directly from mesolimbic dopaminergic pathway activation that NIDA research identifies as functionally identical across immediate-release and extended-release formulations when bioavailability is equivalent.

Mu-Opioid Receptor Binding Mechanism

Oxycodone binds mu-opioid receptors (MOR) in the periaqueductal gray, dorsal horn of the spinal cord, and medullary respiratory center, producing three simultaneous pharmacological effects that explain both its analgesic utility and overdose risk. MOR activation in the ventral tegmental area drives dopamine release into the nucleus accumbens, producing the euphoric reward signal that initiates conditioned drug-seeking behavior. MOR activation in the medullary respiratory center suppresses the hypercapnic ventilatory drive, the primary mechanism of fatal opioid respiratory depression. Oxycodone binds MOR with approximately 1.5 times the affinity of morphine, making it more potent per milligram than the benchmark opioid comparator.

Hepatic Metabolism via CYP3A4 and CYP2D6

Oxycodone undergoes hepatic first-pass metabolism primarily through the cytochrome P450 CYP3A4 pathway, which converts it to the inactive metabolite noroxycodone, and secondarily through CYP2D6, which converts it to oxymorphone, an active metabolite with higher MOR binding affinity than the parent compound. CYP2D6 polymorphisms produce clinically significant variability in oxycodone response: ultra-rapid metabolizers convert a larger fraction to oxymorphone, increasing analgesic and euphoric effects; poor metabolizers produce less oxymorphone, reducing efficacy and potentially reducing abuse liability in this genotype. Drug interactions with CYP3A4 inhibitors such as ketoconazole, erythromycin, and grapefruit juice increase oxycodone plasma concentrations and overdose risk by blocking the primary elimination pathway.

Is Roxicodone Stronger than Other Opioids?

Roxicodone (oxycodone HCl) occupies a mid-tier position in opioid analgesic potency, more potent than codeine and hydrocodone, comparably potent to morphine on an equianalgesic basis, and substantially less potent than hydromorphone, oxymorphone, and fentanyl.

Roxicodone vs. Hydrocodone

Oxycodone is approximately 1.5 times more potent than hydrocodone by equianalgesic dose. Oxycodone 10mg produces approximately equivalent analgesia to hydrocodone 15mg. Both bind mu-opioid receptors as full agonists. Both carry DEA Schedule II classification following the reclassification of hydrocodone combination products from Schedule III in 2014. Clinical studies comparing abuse potential show higher diversion rates for oxycodone relative to hydrocodone, attributed to oxycodone’s higher MOR binding affinity and more pronounced dopaminergic reward signal at equivalent therapeutic doses.

Roxicodone vs. Morphine and the Equianalgesic Table

Standard equianalgesic conversion ratios used in palliative care and pain management position oxycodone at 1.5 times oral morphine potency. The clinical implication is that oral oxycodone 10mg provides analgesia equivalent to oral morphine 15mg. Hydromorphone (Dilaudid) is approximately 5 to 8 times more potent than morphine; oxymorphone (Opana) is approximately 3 times more potent. Fentanyl is 50 to 100 times more potent than morphine, explaining why a counterfeit Roxicodone tablet containing illicitly manufactured fentanyl presents a categorical overdose risk far exceeding any legitimate oxycodone formulation.

When Opioid Use Disorder Risk Begins

Physical dependence to oxycodone develops within 2 to 4 weeks of daily therapeutic use in most patients, reflecting neuroadaptive downregulation of mu-opioid receptor density and uncoupling of MOR from its G-protein signaling cascade. Physical dependence is not opioid use disorder. DSM-5-TR opioid use disorder requires a pattern of compulsive drug-seeking behavior, loss of control over use, and continued use despite clinically significant harm, regardless of whether use began with a legitimate prescription. The Clinical Opiate Withdrawal Scale (COWS) provides standardized measurement of opioid withdrawal severity across 11 parameters, generating scores from 5 to 12 (mild), 13 to 24 (moderate), 25 to 36 (moderately severe), and above 36 (severe), which guide buprenorphine induction timing and dose escalation in clinical detoxification protocols.

Opioid Use Disorder: DSM-5-TR Criteria and Diagnosis

Opioid use disorder, as defined by the DSM-5-TR, is a problematic pattern of opioid use causing clinically significant impairment or distress, diagnosed by the presence of at least 2 of 11 criteria within a 12-month period regardless of whether the opioid used is a legitimate prescription product like Roxicodone or an illicitly obtained counterfeit.

• Tolerance and dose escalation: Markedly increased amounts of oxycodone required to achieve intoxication or desired effect, or a markedly diminished effect with continued use of the same amount
• Withdrawal-driven use: Oxycodone is taken to relieve or avoid withdrawal symptoms including anxiety, myalgia, diaphoresis, and gastrointestinal distress
• Loss of control: Taking oxycodone in larger amounts or over a longer period than intended despite intentions to limit use
• Unsuccessful reduction attempts: Persistent desire or unsuccessful efforts to cut down or control oxycodone use
• Time preoccupation: Significant time spent obtaining, using, or recovering from the effects of oxycodone
• Craving: Strong urge or desire to use oxycodone, frequently experienced as intrusive, difficult to suppress, and triggered by drug-associated environmental cues
• Role failure: Recurrent oxycodone use resulting in failure to fulfill major role obligations at work, school, or home

Opioid Use Disorder Treatment at Riverside Recovery of Tampa

Oxycodone use disorder, including disorder arising from Roxicodone misuse, requires medically supervised detoxification followed by integrated treatment addressing both neurobiological dependence and the behavioral, cognitive, and co-occurring psychiatric dimensions that sustain compulsive opioid use. At Riverside Recovery of Tampa, COWS-guided opioid detox precedes a structured residential and step-down continuum that maintains the same clinical team throughout every level of care.

Medical Detox for Oxycodone Dependence

Riverside Recovery’s medication-assisted treatment (MAT) unit administers buprenorphine/naloxone and methadone under 24-hour supervision by a five-provider medical team.

Extended buprenorphine tapering protocols at Riverside Recovery run 30 or more days, substantially exceeding the industry-standard 5 to 10-day protocol and reflecting ASAM Level 3.7 medically monitored inpatient care standards. No BAC cutoff applies to opioid admissions. The facility handles medically complex opioid patients including those with hepatitis C co-infection, opioid-induced GI dysmotility, and polysubstance co-dependence involving oxycodone and benzodiazepines.

 

“The COWS Score determines buprenorphine induction timing precisely. Patients inducted too early, before adequate opioid clearance, risk precipitated withdrawal. We use COWS measurements every 2 to 4 hours during the induction window to ensure buprenorphine replaces oxycodone dependence through controlled receptor substitution rather than abrupt withdrawal.”

– Assistant Medical Director Erin Ikenberry, PA-C

Residential Treatment

Residential treatment provides 24-hour structured care on the Hillsborough River campus for 30 to 90 days under ASAM Level 3.5 clinically managed high-intensity residential criteria. Twice-weekly individual therapy sessions, daily group therapy incorporating CBT-based relapse prevention and DBT skills training, and DSM-5-TR-informed dual diagnosis evaluation begin within the first 72 hours of residential admission.

Opioid use disorder co-occurs with major depressive disorder in approximately 30 to 40 percent of treatment-seeking patients and with generalized anxiety disorder in approximately 20 to 30 percent, both driven by shared mesolimbic dopaminergic dysregulation. Riverside Recovery conducts Axis I psychiatric evaluations during residential intake to identify co-occurring conditions requiring concurrent pharmacological and psychotherapeutic management alongside opioid use disorder treatment.

Day/Night Treatment and Intensive Outpatient

Evidence-based addiction therapy continues through PHP (Monday through Friday, 9am to 4pm) and IOP (Monday, Tuesday, Thursday, 6pm to 9pm). All outpatient levels include MAT continuation, random urine drug screening, structured 12-step participation with sponsor engagement, and CBT-based relapse prevention addressing oxycodone-specific environmental cue triggers and prescription drug craving patterns. Virtual IOP is available for patients requiring remote access. All treatment programs are covered by most major private insurance, with benefits verified in real time at admission.

Frequently Asked Questions

Are Percocet and Roxicodone the same?

No. Both contain oxycodone HCl as the active ingredient, but Percocet adds acetaminophen 325mg per tablet and is available in strengths up to 10mg oxycodone. Roxicodone contains only oxycodone HCl with no secondary compound, and is available in higher strengths (15mg and 30mg) not found in Percocet. Both are DEA Schedule II immediate-release opioids with identical abuse potential.

Is Roxicodone stronger than hydrocodone?

Yes. Oxycodone is approximately 1.5 times more potent than hydrocodone on an equianalgesic basis. Oxycodone 10mg provides roughly equivalent analgesia to hydrocodone 15mg. Both bind mu-opioid receptors as full agonists. Both are DEA Schedule II. Clinical data shows higher rates of non-medical use for oxycodone relative to hydrocodone, attributed to oxycodone’s stronger dopaminergic reward signal at equivalent therapeutic doses.

What is stronger than oxycodone?

Hydromorphone (Dilaudid) is 5 to 8 times more potent than morphine and approximately 4 times more potent than oxycodone. Oxymorphone (Opana) is 3 times more potent than morphine and approximately 2 times more potent than oxycodone. Fentanyl is 50 to 100 times more potent than morphine. Carfentanil, a veterinary sedative not approved for human use, is approximately 10,000 times more potent than morphine.

What are the top 5 strongest prescription opioids?

Ranked by equianalgesic potency relative to oral morphine: (1) Fentanyl patches and lozenges (50 to 100x morphine); (2) Hydromorphone/Dilaudid (5 to 8x morphine); (3) Oxymorphone/Opana (3x morphine); (4) Methadone (variable, 5 to 10x morphine at higher doses); (5) Oxycodone/Roxicodone (1.5x morphine). All five are DEA Schedule II with high abuse potential and narrow therapeutic-to-lethal dose margins.

What is the difference between Roxicodone and oxycodone HCl?

None pharmacologically. Roxicodone is a brand name; oxycodone HCl is the generic name for the same compound. Both contain oxycodone hydrochloride in identical immediate-release tablet formulations. Generic oxycodone IR offers more strength options (including 10mg and 20mg tablets) than the Roxicodone brand, which is limited to 5mg, 15mg, and 30mg. Cost, availability, and manufacturer identity are the only practical differences.

Does Roxicodone show up on a drug test?

Yes. Oxycodone, including Roxicodone, is detected on standard urine drug screens. Most immunoassay screens include an oxycodone-specific panel separate from the general opiate screen, because oxycodone’s structure differs enough from morphine that standard opiate tests may not reliably detect it. Confirmatory GC-MS or LC-MS/MS testing quantifies oxycodone, noroxycodone, and oxymorphone metabolites. Detection window is approximately 2 to 4 days in urine for therapeutic doses.

Is Roxicodone the same as OxyContin?

Both contain oxycodone HCl, but they are not the same product. Roxicodone is an immediate-release formulation with a 4 to 6-hour duration; OxyContin is an extended-release formulation designed to last 12 hours. Their onset, duration, and misuse risk profiles differ substantially. OxyContin’s higher single-dose oxycodone content (10 to 80mg) and extended release mechanism drove a distinct pattern of extraction and injection misuse during the early opioid epidemic that Roxicodone’s lower-dose immediate-release format does not replicate.

Can someone develop opioid use disorder from a legitimate Roxicodone prescription?

Yes. DSM-5-TR opioid use disorder can develop from any regular opioid exposure, including legitimate prescriptions. Physical dependence develops within 2 to 4 weeks of daily oxycodone use. Whether dependence progresses to opioid use disorder depends on neurobiological vulnerability, genetic factors including MOR gene (OPRM1) variants, co-occurring psychiatric conditions, and duration of exposure. Prescription origin does not reduce disorder risk once neuroadaptive mu-opioid receptor downregulation occurs.

References

1. Centers for Disease Control and Prevention, National Center for Health Statistics. (2023). Drug overdose deaths in the United States, 2001–2022. NCHS Data Brief No. 491.
2. Substance Abuse and Mental Health Services Administration. (2023). National Survey on Drug Use and Health, 2022 results. U.S. Department of Health and Human Services.
3. Drug Enforcement Administration. (2023). National Drug Threat Assessment 2023. U.S. Department of Justice. Retrieved from dea.gov
4. Volkow, N. D., & McLellan, A. T. (2016). Opioid abuse in chronic pain: Misconceptions and mitigation strategies. New England Journal of Medicine, 374(13), 1253–1263.
5. Smith, H. S. (2009). Opioid metabolism. Mayo Clinic Proceedings, 84(7), 613–624.
6. American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). American Psychiatric Publishing.
7. Weiss, R. D., et al. (2015). Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence. Archives of General Psychiatry, 68(12), 1238–1246.
8. American Society of Addiction Medicine. (2020). The ASAM Clinical Practice Guideline on Alcohol, Stimulant, or Benzodiazepine Withdrawal Management. ASAM.